EMBRACE Phase III
The EMBRACE phase III clinical trial (study 305) is the first clinical trial to demonstrate an improvement in overall survival with a chemotherapy treatment, eribulin, in patients with extensively pretreated metastatic breast cancer. This clinical trial led to the approval of eribulin in the US and Europe for this patient group.
DOI: 10.1016/S0140-6736(11)60070-6